Drugs symposium: introduction
R E Ashcroft

Deputy Editor Richard Ashcroft introduces four papers on drugs and autonomy

In this symposium we bring together four papers which consider novel approaches to the use and response to what are popularly known as “drugs”. The language available here is not altogether helpful—the drugs discussed (cannabis, tobacco, cocaine) have very different pharmacological effects, social acceptability, long and short term psychological effects, medical uses, and legal status. Arguably, the effects, social acceptability, long and short term psychological effects, medical uses, and legal status can lead us to a whole series of worries about the extent to which our human capacities of rationality and choice are malleable to (if not determined by) physical interventions in our physical being, the ways in which third parties may for various reasons want to weaken or alter our physical or social bodies, and the ways our present choices may bind our future selves. No wonder public policy is so concerned with drugs!

This concern manifests itself in a whole panoply of decisions, strategies, policies, and regulatory activities, some of which appear to be manifestly irrational. Matti Hayry argues that banning the medicinal use of cannabis is an irrational and indefensible restriction of freedom [see page 333]. His argument could readily be extended to the non medicinal use of cannabis, or to considerations of the injustice of this type of restriction on freedom. A drug which is thought to be far more addictive is tobacco, and it would be interesting to apply Hayry’s arguments to tobacco. Hasman and Holm examine the merits of a type of treatment which could prevent people from becoming addicted to the nicotine component of tobacco—a nicotine conjugate vaccine [see page 344]. Like Hayry, Hasman and Holm are concerned with freedom, in this case the right to an open future. Although some commentators, following the nineteenth century philosopher T H Green, might argue that this sort of restriction on freedom is actually autonomy enhancing, Hasman and Holm are unconvinced by this argument. Carter and Hall, and Ashcroft and Franey examine in more detail another vaccine approach to a drug of addiction, cocaine [see pages 337 and 341]. In these two papers, the authors evaluate the likely social impact of using such a vaccine as either a therapeutic or preventive measure, and concentrate mainly on questions of social justice, rather than individual liberty.

This suite of papers gives a taste of some of the current debates at the cutting edge of drug policy. The UK Government’s Foresight Programme recently initiated a study on “Brain Science, Addiction and Drugs” which will take a 20 year look into the future, examining trends in drug development and other new technologies, to take an informed guess at what the policy issues will be concerning the regulation of drugs and the treatment of addictions. This debate is likely to run and run. As ethicists, two central challenges face us: how far can we be rational about drugs, basing our arguments on autonomy and freedom, when drugs are a standing challenge to the conceptual and empirical basis of those concepts? And how far do our concerns with consistency and rationality help us untangle the curious social worlds of drugs and of drug policy?

doi: 10.1136/jme.2004.009589

Correspondence to: Dr R Ashcroft, Imperial College London, Medical Ethics Unit, 324 Reynolds Building, St Dunstan’s Road, London W6 8RP, UK; r.ashcroft@imperial.ac.uk

REFERENCES
2 Berridge V. Illicit drugs and internationalism: the forgotten dimension. Medical History 2001;45:282-8